Journal of Clinical Endocrinology & Metabolism, Vol 61, 536-540, Copyright © 1985 by Endocrine Society

ARTICLES

Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486

LK Nieman, GP Chrousos, C Kellner, IM Spitz, BC Nisula, GB Cutler, GR Merriam, CW Bardin and DL Loriaux

A patient with Cushing's syndrome due to ectopic ACTH secretion was treated successfully with the new glucocorticoid antagonist RU 486 [17 beta-hydroxy-11 beta-(4-dimethylamino phenyl) 17 alpha-(1- propynyl)estra-4,9-dien-3-one]. This compound is a 19-nor steroid with substitutions at positions C11 and C17 which antagonizes cortisol action competitively at the receptor level. Oral RU 486 was given in increasing doses of 5, 10, 15, and 20 mg/kg . day for a 9-week period. Treatment efficacy was monitored by assessment of clinical status and by measuring several glucocorticoid-sensitive variables, including fasting blood sugar, blood sugar 120 min after oral glucose administration, and plasma concentrations of TSH, corticosteroid- binding globulin, LH, testosterone-estradiol-binding globulin, and total and free testosterone. With therapy, the somatic features of Cushing's syndrome (buffalo hump, central obesity, and moon facies) ameliorated, mean arterial blood pressure normalized, suicidal depression resolved, and libido returned. All biochemical glucocorticoid-sensitive parameters normalized. No side-effects of drug toxicity were observed. We conclude that RU 486 may provide a safe, well tolerated, and effective medical treatment for hypercortisolism.

This article has been cited by other articles:

				P. A Cassier, S. Abou-Amara-Olivieri, P. Artru, M.-G. Lapalus, J.-P. Riou, and C. Lombard-Bohas Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur. J. Endocrinol., June 1, 2008; 158(6): 935 - 938. [Abstract] [Full Text] [PDF]

				S. Johanssen and B. Allolio Mifepristone (RU 486) in Cushing's syndrome Eur. J. Endocrinol., November 1, 2007; 157(5): 561 - 569. [Abstract] [Full Text] [PDF]

				F. M. Horne and D. L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Hum. Reprod. Update, November 1, 2007; 13(6): 567 - 580. [Abstract] [Full Text] [PDF]

				P. B. Jacobson, T. W. von Geldern, L. Ohman, M. Osterland, J. Wang, B. Zinker, D. Wilcox, P. T. Nguyen, A. Mika, S. Fung, et al. Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 191 - 200. [Abstract] [Full Text] [PDF]

				J. Rosen and J. N. Miner The Search for Safer Glucocorticoid Receptor Ligands Endocr. Rev., May 1, 2005; 26(3): 452 - 464. [Abstract] [Full Text] [PDF]

				Y. Liu, Y. Nakagawa, Y. Wang, R. Sakurai, P. V. Tripathi, K. Lutfy, and T. C. Friedman Increased Glucocorticoid Receptor and 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in Hepatocytes May Contribute to the Phenotype of Type 2 Diabetes in db/db Mice Diabetes, January 1, 2005; 54(1): 32 - 40. [Abstract] [Full Text] [PDF]

				P. Alberts, C. Nilsson, G. Selen, L. O. M. Engblom, N. H. M. Edling, S. Norling, G. Klingstrom, C. Larsson, M. Forsgren, M. Ashkzari, et al. Selective Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains Endocrinology, November 1, 2003; 144(11): 4755 - 4762. [Abstract] [Full Text] [PDF]

				M. D. Passaro, J. Piquion, N. Mullen, D. Sutherland, S. Zhai, W. D. Figg, R. Blye, and L. K. Nieman Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women Hum. Reprod., September 1, 2003; 18(9): 1820 - 1827. [Abstract] [Full Text] [PDF]

				O. Heikinheimo, T. Raivio, H. Honkanen, S. Ranta, and O. A. Janne Termination of Pregnancy with Mifepristone and Prostaglandin Suppresses Transiently Circulating Glucocorticoid Bioactivity J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 323 - 326. [Abstract] [Full Text] [PDF]

				J. N. Miner, C. Tyree, J. Hu, E. Berger, K. Marschke, M. Nakane, M. J. Coghlan, D. Clemm, B. Lane, and J. Rosen A Nonsteroidal Glucocorticoid Receptor Antagonist Mol. Endocrinol., January 1, 2003; 17(1): 117 - 127. [Abstract] [Full Text] [PDF]

				D. MORRIS and A. GROSSMAN The Medical Management of Cushing's Syndrome Ann. N.Y. Acad. Sci., September 1, 2002; 970(1): 119 - 133. [Abstract] [Full Text] [PDF]

				T. Raivio, J. J. Palvimo, S. Kannisto, R. Voutilainen, and O. A. Janne Transactivation Assay for Determination of Glucocorticoid Bioactivity in Human Serum J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3740 - 3744. [Abstract] [Full Text] [PDF]

				J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3568 - 3573. [Abstract] [Full Text] [PDF]

				D. A. Scheuer and S. W. Mifflin Glucocorticoids modulate baroreflex control of renal sympathetic nerve activity Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1440 - R1449. [Abstract] [Full Text] [PDF]

				C. M. Meston and P. F. Frohlich The Neurobiology of Sexual Function Arch Gen Psychiatry, November 1, 2000; 57(11): 1012 - 1030. [Abstract] [Full Text] [PDF]

				R. S. Newfield, G. Kalaitzoglou, T. Licholai, D. Chilton, J. Ashraf, E. B. Thompson, and M. I. New Normocortisolemic Cushing's Syndrome Initially Presenting with Increased Glucocorticoid Receptor Numbers J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 14 - 21. [Abstract] [Full Text]

				O. M. Wolkowitz and V. I. Reus Treatment of Depression With Antiglucocorticoid Drugs Psychosom Med, September 1, 1999; 61(5): 698 - 711. [Abstract] [Full Text] [PDF]

				J. R. Goldberg, M. G. Plescia, and G. D. Anastasio Mifepristone (RU 486): Current Knowledge and Future Prospects Arch Fam Med, June 1, 1998; 7(3): 219 - 222. [Abstract] [Full Text] [PDF]

				D. N. Orth Cushing's Syndrome N. Engl. J. Med., March 23, 1995; 332(12): 791 - 803. [Full Text] [PDF]

				I. M. Spitz and C.W. Bardin Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action N. Engl. J. Med., August 5, 1993; 329(6): 404 - 412. [Full Text]

				E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science, September 22, 1989; 245(4924): 1351 - 1357. [Abstract] [PDF]